Aventis submits additional Ketek information
Executive Summary
Aventis submits additional analysis of clinical studies and postmarketing surveillance data in response to FDA's Jan. 24 "approvable" letter for antibiotic Ketek (telithromycin). The company filed additional safety data in 2002 following a June 2001 "approvable" letter (1"The Pink Sheet" Nov. 4, 2002, p. 16)...
You may also be interested in...
Aventis Ketek Will Return To FDA Advisory Committee Jan. 8
FDA's Anti-Infective Drugs Advisory Committee will review the safety profile of Aventis' Ketek (telithromycin) on Jan. 8, Exec VP-Commercial Operations Thierry Soursac told an investor conference call Oct. 29
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.